<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T04:09:27Z</responseDate>
  <request identifier="oai:figshare.com:article/34054605" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34054605</identifier>
        <datestamp>2026-10-02T05:37:32Z</datestamp>
        <setSpec>category_696</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Data Sheet 1_Split intein-mediated reconstitution of regulatable CAR T-cells.pdf</dc:title>
          <dc:creator>Vladimir Mulens-Arias (8702370)</dc:creator>
          <dc:creator>Marco Archinti (25162668)</dc:creator>
          <dc:creator>Miriam Bastida (25162671)</dc:creator>
          <dc:creator>Nuria Martínez (25162674)</dc:creator>
          <dc:creator>Eleonora Pinto (3418427)</dc:creator>
          <dc:creator>Víctor M. Díaz (9184031)</dc:creator>
          <dc:creator>Pablo Menéndez (5662426)</dc:creator>
          <dc:subject>Genetic Immunology</dc:subject>
          <dc:subject>CAR T-cells</dc:subject>
          <dc:subject>immunotherapy</dc:subject>
          <dc:subject>modular</dc:subject>
          <dc:subject>protein trans-splicing</dc:subject>
          <dc:subject>split inteins</dc:subject>
          <dc:description>Introduction&lt;p&gt;Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies. However, strategies that improve the modularity and controllability of CAR signaling could broaden its applicability and safety across additional clinical contexts. Here, we describe a regulable CAR T-cell platform based on split intein-mediated protein trans-splicing (PTS) to conditionally reconstitute functional receptors in primary T-cells.&lt;/p&gt;Methods&lt;p&gt;As a proof of concept, we engineered a split CAR targeting CD1a (NCT05679895), a surface antigen expressed in T-cell acute lymphoblastic leukemia (T-ALL). The system consists of a membrane-anchored C-terminal scaffold containing the IMPDH.1&lt;sup&gt;C&lt;/sup&gt; split intein fused to 4-1BB and CD3ζ signaling domains, and a soluble N-terminal adaptor composed of an anti-CD1a single-chain variable fragment (scFv) fused to the complementary IMPDH.1&lt;sup&gt;N&lt;/sup&gt; split intein. &lt;/p&gt;Results&lt;p&gt;Upon delivery of the adaptor module, the intein fragments undergo PTS, generating a functional membrane-bound CD1a CAR with splicing efficiencies of 85%. Reconstituted CAR T-cells exhibited antigen-specific cytotoxicity against CD1a&lt;sup&gt;+&lt;/sup&gt; T-ALL cells coupled to high levels of interferon-γ secretion. &lt;/p&gt;Discussion&lt;p&gt;These findings demonstrate that split intein-mediated CAR reconstitution enables a modular platform for conditional CAR reconstitution and transient control of receptor availability. &lt;/p&gt;</dc:description>
          <dc:date>2026-10-02T05:37:32Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fimmu.2026.1844972.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Data_Sheet_1_Split_intein-mediated_reconstitution_of_regulatable_CAR_T-cells_pdf/34054605</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
